You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.
Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.
At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.
S&P Healthcare Credit Beat - Episode 3: Four Takeaways - DaVita
Credit FAQ: Bausch Health Companies Inc.: What’s The Credit Quality Following Spinoff Of Eye-Care Unit?
The S&P Pharma Dose - Episode 36: What Bausch RemainCo’s Credit Quality Post-Spinoff Could Look Like
European Office Real Estate Companies: After A Resilient First Half, Upcoming Lease Maturities Should Test The Market
COVID-19 Impact: Key Takeaways From Our Articles
Top two U.S. dialysis player, DaVita, has seen its fair share of headlines over the past year – an upcoming California ballot on dialysis reimbursement, charitable premium assistance controversy, and a pending sale of DMG. What does all this mean for DaVita’s ratings? Healthcare analysts, Ji Liu and Arthur Wong, discuss on the Beat what they are focusing on for the ratings on DaVita.